Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.

Jüergen Braun Uta KiltzAtul DeodharTetsuya TomitaMaxime DougadosRebecca BolceDavid SandovalChen-Yen LinJessica Walsh

Published in: RMD open (2022)

IXE treatment led to sustained long-term improvements in patients with axSpA, with similar efficacy for r-axSpA and nr-axSpA, and for patients receiving the approved every 4 weeks dose. The safety profile of IXE was consistent with previous reports. No new safety signals were identified.

Keyphrases

emergency department
systemic lupus erythematosus
ankylosing spondylitis
combination therapy
disease activity
gestational age